{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:53:01Z","timestamp":1791003181127,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s40263-020-00759-9","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T20:02:46Z","timestamp":1598472166000},"page":"1105-1120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-0083","authenticated-orcid":false,"given":"Simona","family":"Lattanzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Zaccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Del Giovane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Silvestrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Brigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"759_CR1","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1212\/01.wnl.0000252807.38124.a3","volume":"68","author":"D Hirtz","year":"2007","unstructured":"Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the \u201ccommon\u201d neurologic disorders? Neurology. 2007;68:326\u201337.","journal-title":"Neurology"},{"key":"759_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1212\/WNL.0000000000000619","volume":"83","author":"C Cagnetti","year":"2014","unstructured":"Cagnetti C, Lattanzi S, Foschi N, Provinciali L, Silvestrini M. Seizure course during pregnancy in catamenial epilepsy. Neurology. 2014;83:339\u201344.","journal-title":"Neurology"},{"key":"759_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","volume":"346","author":"OC Cockerell","year":"1995","unstructured":"Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the national general practice study of epilepsy. Lancet. 1995;346:140\u20134.","journal-title":"Lancet"},{"key":"759_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/ane.13025","volume":"139","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S, Zaccara G, Giovannelli F, Grillo E, Nardone R, Silvestrini M, Trinka E, Brigo F. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Acta Neurol Scand. 2019;139:33\u201341.","journal-title":"Acta Neurol Scand"},{"key":"759_CR5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","volume":"342","author":"P Kwan","year":"2000","unstructured":"Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314\u20139.","journal-title":"N Engl J Med"},{"key":"759_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.seizure.2015.03.003","volume":"27","author":"S Lattanzi","year":"2015","unstructured":"Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Lacosamide monotherapy for partial onset seizures. Seizure. 2015;27:71\u20134.","journal-title":"Seizure"},{"key":"759_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.yebeh.2014.05.031","volume":"37","author":"KD Laxer","year":"2014","unstructured":"Laxer KD, Trinka E, Hirsch LJ, Cendes F, Langfitt J, Delanty N, Resnick T, Benbadis SR. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59\u201370.","journal-title":"Epilepsy Behav"},{"key":"759_CR8","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/epi.13723","volume":"58","author":"CB Josephson","year":"2017","unstructured":"Josephson CB, Patten SB, Bulloch A, Williams JVA, Lavorato D, Fiest KM, Secco M, Jette N. The impact of seizures on epilepsy outcomes: a national, community-based survey. Epilepsia. 2017;58:764\u201371.","journal-title":"Epilepsia"},{"key":"759_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","volume":"75","author":"Z Chen","year":"2018","unstructured":"Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279\u201386.","journal-title":"JAMA Neurol"},{"key":"759_CR10","unstructured":"FDA. Cenobamate. Full prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212839s000lbl.pdf. Accessed May 2020."},{"key":"759_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.eplepsyres.2012.10.001","volume":"103","author":"M Bialer","year":"2013","unstructured":"Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 2013;103:2\u201330.","journal-title":"Epilepsy Res"},{"key":"759_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","volume":"855","author":"M Nakamura","year":"2019","unstructured":"Nakamura M, Cho JH, Shin H, Jang IS. Neuropharmacology and analgesia effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019;855:175\u201382.","journal-title":"Eur J Pharmacol"},{"key":"759_CR13","doi-asserted-by":"publisher","first-page":"173117","DOI":"10.1016\/j.ejphar.2020.173117","volume":"879","author":"R Sharma","year":"2020","unstructured":"Sharma R, Nakamura M, Neupane C, Jeon BH, Shin H, Melnick SM, Glenn KJ, Jang IS, Park JB. Positive allosteric modulation of GABA(A) receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol. 2020;879:173117.","journal-title":"Eur J Pharmacol"},{"key":"759_CR14","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"759_CR15","unstructured":"FDA. Drug approval package: Xcopri (Cenobamate), NDA 212839, FDA Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212839Orig1s000TOC.cfm. Accessed May 2020."},{"key":"759_CR16","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. In: Higgins JPT, Green S, editors. The Cochrane Collaboration, 2011. http:\/\/handbook-5-1.cochrane.org\/. Accessed May 2020."},{"key":"759_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"759_CR18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"759_CR19","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","volume":"78","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, Silvestrini M. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs. 2018;78:1791\u2013804.","journal-title":"Drugs"},{"key":"759_CR20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-018-0558-9","volume":"32","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Cagnetti C, Trinka E, Silvestrini M. Efficacy and safety of adjunctive cannabidiol in patients with Lennox\u2013Gastaut syndrome: a systematic review and meta-analysis. CNS Drugs. 2018;32:905\u201316.","journal-title":"CNS Drugs"},{"key":"759_CR21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s40263-020-00708-6","volume":"34","author":"S Lattanzi","year":"2020","unstructured":"Lattanzi S, Brigo F, Trinka E, Zaccara G, Striano P, Del Giovane C, Silvestrini M. Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs. 2020;34:229\u201341.","journal-title":"CNS Drugs"},{"key":"759_CR22","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40265-019-01069-1","volume":"79","author":"S Lattanzi","year":"2019","unstructured":"Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, Silvestrini M. Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs. 2019;79:417\u201331.","journal-title":"Drugs"},{"key":"759_CR23","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00415-017-8505-0","volume":"264","author":"S Lattanzi","year":"2017","unstructured":"Lattanzi S, Cagnetti C, Danni M, Provinciali L, Silvestrini M. Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis. J Neurol. 2017;264:1697\u2013704.","journal-title":"J Neurol"},{"key":"759_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000488401","volume":"45","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Cagnetti C, Di Napoli M, Silvestrini M. Patent foramen ovale and cryptogenic stroke or transient ischemic attack: to close or not to close? A systematic review and meta-analysis. Cerebrovasc Dis. 2018;45:193\u2013203.","journal-title":"Cerebrovasc Dis"},{"key":"759_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00415-017-8681-y","volume":"265","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Grillo E, Brigo F, Silvestrini M. Efficacy and safety of perampanel in Parkinson\u2019s disease. A systematic review with meta-analysis. J Neurol. 2018;265:733\u201340.","journal-title":"J Neurol"},{"key":"759_CR26","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, Rosenfeld WE, Sperling MR, Mizne S, Kamin M. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94:e2311\u201322.","journal-title":"Neurology"},{"key":"759_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","volume":"19","author":"GL Krauss","year":"2020","unstructured":"Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, Steinhoff BJ, Kamin M. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19:38\u201348.","journal-title":"Lancet Neurol"},{"key":"759_CR28","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/j.1528-1167.2010.02952.x","volume":"52","author":"DC Hesdorffer","year":"2011","unstructured":"Hesdorffer DC, Tomson T, Benn E, Sander JW, Nilsson L, Langan Y, Walczak TS, Beghi E, Brodie MJ, Hauser A, ILAE Commission on Epidemiology, Subcommission on Mortality. Combined analysis of risk factors for SUDEP. Epilepsia. 2011;52:1150\u20139.","journal-title":"Epilepsia"},{"key":"759_CR29","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/j.1528-1167.2011.03047.x","volume":"52","author":"J Costa","year":"2011","unstructured":"Costa J, Fareleira F, Ascen\u00e7\u00e3o R, Borges M, Sampaio C, Vaz-Carneiro A. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia. 2011;52:1280\u201391.","journal-title":"Epilepsia"},{"key":"759_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1535759720903032","volume":"20","author":"DG Vossler","year":"2020","unstructured":"Vossler DG. Remarkably high efficacy of cenobamate in adults with focal-onset seizures: a double-blind, randomized, placebo-controlled trial. Epilepsy Curr. 2020;20:85\u20137.","journal-title":"Epilepsy Curr"},{"key":"759_CR31","unstructured":"Sperling M, Klein P, Kamin M. Safety of cenobamate (YKP3089) as adjunctive treatment for uncontrolled partial seizures in a large, multicenter, open-label study. In: The American Epilepsy Society annual meeting. New Orleans, LA, November 30\u2013December 4, 2018. Abstract 1.303. https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/500991. Accessed May 2020."},{"key":"759_CR32","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/j.1528-1167.2007.01041.x","volume":"48","author":"G Zaccara","year":"2007","unstructured":"Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48:1223\u201344.","journal-title":"Epilepsia"},{"key":"759_CR33","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1111\/epi.14591","volume":"59","author":"EP Borrelli","year":"2018","unstructured":"Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, Caffrey AR. Stevens\u2013Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US Food and Drug Administration Adverse Event Reporting System. Epilepsia. 2018;59:2318\u201324.","journal-title":"Epilepsia"},{"key":"759_CR34","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1212\/WNL.49.2.542","volume":"49","author":"P Tennis","year":"1997","unstructured":"Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology. 1997;49:542\u20136.","journal-title":"Neurology"},{"key":"759_CR35","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, Rosenfeld WE, Vossler DG, Wechsler R, Borchert L, Kamin M. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61:1099\u2013108.","journal-title":"Epilepsia"},{"key":"759_CR36","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1528-1167.2006.00423.x","volume":"47","author":"LJ Hirsch","year":"2006","unstructured":"Hirsch LJ, Weintraub DB, Buchsbaum R, et al. Predictors of lamotrigine-associated rash. Epilepsia. 2006;47:318\u201322.","journal-title":"Epilepsia"},{"key":"759_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41582-019-0309-7","volume":"16","author":"JA French","year":"2020","unstructured":"French JA. Cenobamate for focal seizures\u2014a game changer? Nat Rev Neurol. 2020;16:133\u20134.","journal-title":"Nat Rev Neurol"},{"key":"759_CR38","unstructured":"Chung SS, French J, Krauss GL, Lee SK, Maciejowski M, Rosenfeld WE, Sperling MR, Kamin M. Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. In: The American Academy of Neurology annual meeting, Toronto, Canada, April 25\u2013May 1, 2020. Abstract S25.006. https:\/\/index.mirasmart.com\/AAN2020\/SearchResults.php?Topic=&Author_Institution=&Author=&Title=Long-term+Safety+of+Adjunctive+Cenobamate+in+Patients+with+Uncontrolled+Focal+Seizures%3A+Open-label+Extension+of+a+Randomized+Clinical+Study+. Accessed July 2020."},{"key":"759_CR39","unstructured":"Krauss G, Klein P, Aboumatar S, Kamin M. Long-term efficacy and safety of adjunctive cenobamate in patients with uncontrolled focal seizures: open-label extension of a randomized clinical study. The American Academy of Neurology annual meeting, Toronto, Canada, April 25\u2013May 1, 2020. Abstract S59.009. https:\/\/index.mirasmart.com\/AAN2020\/SearchResults.php?text=&Topic=&Author_Institution=&Author=&Title=Long-term+Efficacy+and+Safety+of+Adjunctive+Cenobamate+in+Patients+With+Uncontrolled+Focal+Seizures%3A+Open-label+Extension+of+a+Randomized+Clinical+Study+. Accessed July 2020."},{"key":"759_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/ane.13249","volume":"142","author":"G Zaccara","year":"2020","unstructured":"Zaccara G, Lattanzi S, Cincotta M, Russo E. Drug treatments in patients with cardiac diseases and epilepsy. Acta Neurol Scand. 2020;142:37\u201349.","journal-title":"Acta Neurol Scand"},{"key":"759_CR41","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.yebeh.2019.05.038","volume":"97","author":"G Zaccara","year":"2019","unstructured":"Zaccara G, Lattanzi S. Comorbidity between epilepsy and cardiac arrhythmias: implication for treatment. Epilepsy Behav. 2019;97:304\u201312.","journal-title":"Epilepsy Behav"},{"issue":"Suppl S1","key":"759_CR42","first-page":"S91","volume":"103","author":"L Vernillet","year":"2018","unstructured":"Vernillet L, Kamin M. Drug\u2013drug interactions between cenobamate and other antiepileptic drugs: results from phase I studies with carbamazepine, phenobarbital, phenytoin, and divalproex sodium [abstract]. Clin Pharmacol Ther. 2018;103(Suppl S1):S91.","journal-title":"Clin Pharmacol Ther"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00759-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-020-00759-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00759-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T23:19:56Z","timestamp":1629933596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-020-00759-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["759"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00759-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"assertion":[{"value":"26 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 Politecnica delle Marche within the CRUI-CARE Agreement. No funding has been received for the conduct of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Simona Lattanzi has received speaker\u2019s or consultancy fees from Eisai, UCB Pharma, and GW Pharmaceuticals and has served on an advisory board for GW Pharmaceuticals. Eugen Trinka received speaker\u2019s honoraria from UCB Pharma, Biogen, Gerot-Lannach, Bial, Eisai, Takeda, Newbridge, Sunovion Pharmaceuticals Inc., LivaNova, and Novartis; consultancy funds from UCB Pharma, Biogen, Gerot-Lannach, Bial, Eisai, Takeda, Newbridge, GW Pharmaceuticals, Sunovion Pharmaceuticals Inc., and Novartis; and directorship funds from Neuroconsult GmbH. E. Trinka\u2019s institution received grants from Biogen, Red Bull, Merck, UCB Pharma, European Union, FWF \u00d6sterreichischer Fond zur Wissenschaftsf\u00f6rderung, and Bundesministerium f\u00fcr Wissenschaft und Forschung. Gaetano Zaccara received speaker\u2019s or consultancy fees from Eisai, Sanofi-Aventis, and UCB Pharma. Pasquale Striano received fees and research grants from GW Pharmaceuticals, Zogenyx, Biomarin, and Kolfarma s.r.l. Cinzia Del Giovane and Mauro Silvestrini have no conflicts of interest directly relevant to the content of this study. Francesco Brigo acted as a consultant for Eisai.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All authors approved the final manuscript for submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"SL drafted the concept, analyzed data, and wrote the manuscript. SL and GZ performed the literature search. ET, GZ, PS, CDG, MS, and FB critically revised the work. All authors contributed to the final manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}